CHRM1 and ulcerative colitis: Lastly, animal studies are required to demonstrate both the efficacy and safety of M1R agonism in models of both sporadic and colitis-associated colon cancer; a report that McN-A-343 treatment reduces inflammation and oxidative stress in a murine model of ulcerative colitis suggests promise for the latter indication [46].